Menu
Joint Clinical Trials Office

You are here

Home
Randomized Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ANVIL)
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 20, 2019
Randomized Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ANVIL)
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 20, 2019
Randomized Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ANVIL)
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 20, 2019
Randomized Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ANVIL)
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 20, 2019
Randomized Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ANVIL)
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 20, 2019
Randomized Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ANVIL)
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 20, 2019
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 25, 2019
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 25, 2019
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 25, 2019
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 25, 2019